2025 ATA thyroglobulin cutoff may miss recurrences in higher-risk DTC

A retrospective study of 205 patients with differentiated thyroid cancer treated with total thyroidectomy without radioactive iodine evaluated the revised 2025 ATA thyroglobulin cutoff of 2.5 ng/mL. The study reported that this threshold increased the excellent response classification from 76% to 98% and missed no recurrences among ATA low-risk patients, but 3.5% of patients with low-intermediate or higher-risk disease had structural recurrence despite meeting excellent response criteria, with a postoperative Tg cutoff of 0.3 ng/mL showing 100% sensitivity for recurrence in that group.

Most relevant for: Patients with differentiated thyroid cancer classified as low-intermediate or higher ATA recurrence risk after total thyroidectomy without radioactive iodine.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.